Overall, these data demonstrate prominent expression of FcγRIIIa in treatment-naïve TNBC tumors proximal to the tumor antigen–expressing cells, suggesting a potential therapeutic opportunity for FcγRIIIa-enhanced antibodies. This evidence concerns the gene FCGR3A and neoplasm.